A study shows how a class of drugs, HDACi (histone deacetylase inhibitors), protects neurons and limits brain damage ...

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 70+ ...

Rakovina's platform has already attracted interest from multiple pharmaceutical companies seeking differentiated assets and AI-powered discovery capabilities. The Company anticipates that upcoming ...

Investigators from Anthem Biosciences Ltd. have published preclinical characterization data on their histone deacetylase (HDAC) inhibitor PAT-1102 for the potential treatment of cancer.

Privately-held Italian pharma company Italfarmaco today revealed that the European Commission (EC) has granted conditional ...

This review highlights how air pollution and occupational inhalation exposures may contribute to neurodegenerative disorders ...

I Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of ...

BASFY starts registration for Adapzo Active, a breakthrough fungicide tackling resistant Asian Soybean Rust strains.

Belgian company Augustine Therapeutics has initiated subject dosing in the randomised Phase I trial of AGT-100216, a selective histone deacetylase 6 (HDAC6) inhibitor, targeting the treatment of ...

The desirable properties of histone deacetylase inhibitors as therapeutics for treating endometriosis are enumerated, and the obstacles in evaluating histone deacetylases in clinical trials are ...